Research Radartracking 1,189 published studies · 293 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Pineoblastoma

A plain-English summary of the published research on Pineoblastoma, reviewed and approved by our editors — not a hand-curated clinical overview.

Research summary · reviewed
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 · OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Jun 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
32 published studies that name Pineoblastoma8 human studies approved & graded (trial, observational, or meta-analysis)23 human clinical studies in the Pineoblastoma corpus325 source documents in the Pineoblastoma corpus

last checked June 19, 2026

Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

  • 8 human · 2 animal · 0 lab · 22 review/other
  • Most authoritative study: A systematic review of adult pineoblastoma
  • Studies disagree on the reported direction (conflict flagged).
  • Findings conflict across studies
  • Effect sizes reported in only 11 of 32 studies

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Studied, not standard - investigational
  • surgical resection
  • endoscopic surgery
  • proton beam therapy
  • craniospinal irradiation
  • Gamma Knife radiosurgery
  • cisplatin-based chemotherapy
  • high-dose chemotherapy + ABMT
  • Methotrexate

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Pineoblastoma.

Treatment map: Pineoblastoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

9
Interventions
0
Standard of care
9
Tested in people
0
Lab / animal
0
Named in lit.
4
Classes
Standard of care (0) Guideline option (0) Tested in people (9) Lab / animal only (0) Named in the literature (0)

Tested in people, by trial phase: Phase III ×1 · phase not reported ×8

Investigational & adjunct compounds — detail (9)
Phase III trial (1)
Methotrexateoff-label
Meta-analysis (8)
cisplatin-based chemotherapycraniospinal irradiation· Adjuvant (after surgery)endoscopic surgeryGamma Knife radiosurgery· First-line (advanced disease)Gamma Knife radiosurgeryhigh-dose chemotherapy + ABMTproton beam therapysurgical resection

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Pineoblastoma
A monthly email when the research changes — $10/mo. Manage follows
Follow Pineoblastoma

Snapshot

The essentials in ~60 seconds — every line is drawn from the cited sources below.

What it is
Pineoblastoma is a rare, WHO grade IV pineal parenchymal tumour that mainly arises at a younger age and is prone to spreading through the cerebrospinal fluid, so staging must document localized versus disseminated disease. [1][2][3]
Survival
In a pooled series of 108 adult cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. [2]
Standard treatment
Diagnosis is driven by imaging with histologic confirmation by biopsy except for certain germ cell tumours identified by markers; management commonly involves surgical resection (aiming for gross- or subtotal resection) with malignant tumours frequently followed by chemotherapy and radiotherapy, and receipt of radiotherapy was associated with lower hazard of death in a pooled adult series. [1][2]
Key test
Measure AFP and HCG in serum/CSF to identify pineal-region germ cell tumours (which can obviate biopsy); molecular classification into PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC defines distinct clinico-pathologic and survival subgroups. [1][2]
Biggest challenge
The main clinical problems are a high rate of recurrence with a propensity for CSF dissemination and very limited adult-specific evidence to clarify optimal treatment approaches. [2][3]

Ask about Pineoblastoma

Answers come only from the cited sources on this page — with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

Key numbers & factors

Biomarkers

  • AFP / HCGActionableidentify pineal-region germ cell tumours in serum/CSF and may obviate biopsy [1]
  • Molecular subgroup (PB-Group 1, PB-Group 2, PB-Group 3, RB, MYC) · classify pineoblastoma into prognostic clinico-pathologic groups [2]

9 sections — tap any heading to expand its cited detail. Key points are above.

OverviewPineal region tumours are rare, mainly arise at a younger age, and include pineoblastoma among other histologies. Pineoblastoma is classified as a WHO grade IV tumour with a high rate of recurrence and propensity for spread via the cerebrospinal fluid (CSF).2 points
  • Pineal region tumours are rare, mainly arise at a younger age, and include pineoblastoma among other histologies. [1]
  • Pineoblastoma is classified as a WHO grade IV tumour with a high rate of recurrence and propensity for spread via the cerebrospinal fluid (CSF). [2]
EpidemiologyPineal region tumours are rare. Primary pineal tumours make up a small fraction of intracranial malignancies, pineal tumours are a heterogeneous group in children, and pineoblastoma is a common pineal parenchymal subtype.3 points
  • Primary tumours of the pineal gland are rare and account for 0.1%-0.3% of intracranial malignancies. [2]
  • Pineoblastoma accounts for approximately 45% of all pineal parenchymal tumour subtypes. [2]
  • Tumours of the pineal region represent a rare and heterogeneous group of pediatric intracranial neoplasms, accounting for 3-8% of childhood brain tumors in published series. [3]
Key biomarkersGerm cell tumours in the pineal region — but not pineoblastoma — can sometimes be identified by elevated tumour markers in CSF and serum such as alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG). Recent molecular characterisation has segregated pineoblastoma into five molecular subgroups (PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC) with distinct clinico-pathologic and survival features.2 points
  • Germ cell tumours in the pineal region — but not pineoblastoma — can sometimes be identified by elevated tumour markers such as alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in CSF and serum. [1]
  • Recent molecular characterisation has segregated pineoblastoma into five molecular subgroups: PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC, each with distinct clinico-pathologic and survival features. [2]
Standard managementPineal region tumors are typically evaluated with imaging and require histologic diagnosis by biopsy except when specific germ cell tumor markers identify the lesion; they commonly produce obstructive hydrocephalus and mass-effect symptoms such as headache, nausea, vomiting, and impaired gait stability. Management centers on surgical resection — benign pineal region tumors may be managed with radical resection alone, while malignant tumors commonly require additional chemotherapy and radiotherapy after surgical removal.3 points
  • Imaging is the primary diagnostic tool for pineal region tumours, and histologic diagnosis requires biopsy except for certain germ cell tumours identified by markers. [1]
  • These tumours often lead to obstructive hydrocephalus and commonly cause symptoms related to mass effect such as headache, nausea, vomiting, and impaired gait stability. [1]
  • Benign pineal region tumours may be treated with radical resection alone whereas malignant tumours often require additional chemotherapy and radiotherapy after surgical removal. [1]
Treatments & compounds studiedEight entries covering procedure_device, radiotherapy, and chemotherapy approaches to pineoblastoma are reported.8 treatments

Chemotherapy

  • cisplatin-based chemotherapy: Chemotherapy regimens reported in adult pineoblastoma series varied considerably, and where reported a cisplatin-based schedule was used in the majority of patients who received chemotherapy. [2]
  • high-dose chemotherapy + ABMT: Some paediatric series of pineal/medulloblastoma-type tumours included high-dose chemotherapy with autologous bone marrow transplant (ABMT) as part of multimodality treatment prior to proton therapy. [4]

Radiotherapy

  • proton beam therapy: Proton beam therapy has been adopted as the primary radiotherapy modality for selected paediatric CNS tumours in children and young adults (age up to 25 years), providing smaller volumes of non-target irradiated normal tissue compared with photon radiotherapy largely due to the near complete elimination of exit dose. [4]
  • craniospinal irradiation: Adjuvant (after surgery)In a pooled series of adult pineoblastoma cases, the majority (94 of 108) received adjuvant radiotherapy and of those, 51 (54.3%) were treated with craniospinal irradiation (CSI). [2]
  • Gamma Knife radiosurgery · 2 findings
    • First-line (advanced disease)Gamma Knife stereotactic radiosurgery (GKSR) as primary treatment for pineal region tumours achieved local control in 80.3% of cases at a median 36-month follow-up in a pooled analysis. [5]
      local control 80.3%overall mortality 13.2%radionecrosis rate 6%
      Source quotes
      • “At a median 36-month follow-up, local control was achieved in 80.3% of cases.”
      • “Overall mortality was 13.2%.”
      • “The radionecrosis rate was 6%, and cystic degeneration was observed in 2%.”
    • In the pooled Gamma Knife series, overall mortality was 13.2% and the radionecrosis rate was 6%. [5]
      local control 80.3%overall mortality 13.2%radionecrosis rate 6%
      Source quotes
      • “At a median 36-month follow-up, local control was achieved in 80.3% of cases.”
      • “Overall mortality was 13.2%.”
      • “The radionecrosis rate was 6%, and cystic degeneration was observed in 2%.”

Procedures & devices

  • surgical resection: Microsurgical approaches for pineal region tumours include supracerebellar infratentorial (SCITA), occipital transtentorial (OTA), occipital interhemispheric transtentorial (OITA), and transcallosal routes, and endoscopic or endoscope-assisted techniques are also used. [3]
  • endoscopic surgery: Minimally invasive (endoscopic) techniques increasingly complement traditional microsurgical routes to reduce morbidity and improve CSF management. [3]
Staging & risk1 point
  • Sources describe pineoblastoma as having a high rate of recurrence and a propensity to spread via the cerebrospinal fluid (CSF); staging should therefore document whether disease is localized or disseminated. [2]
PrognosisIn a pooled series of 108 adult pineoblastoma cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. In multivariate analysis, receipt of radiotherapy was associated with a substantially lower hazard of death (HR 0.16; p < 0.001), and patients who underwent surgery (GTR or STR) had superior overall survival at 5 and 10 years.3 points
  • In a pooled series of 108 adult pineoblastoma cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. [2]
  • In multivariate analysis of the pooled adult series, receipt of radiotherapy was associated with a statistically significant lower hazard of death (HR 0.16; p < 0.001). [2]
  • Kaplan–Meier analysis in the pooled adult series showed that patients who underwent surgery (GTR or STR) had superior overall survival at 5 and 10 years (p = 0.009, p = 0.018). [2]
Safety & interactionsProton beam therapy may reduce late adverse events by reducing irradiation of non-target normal tissue compared with photon radiotherapy, but the evidence comes mainly from non-randomised studies and modelling assumptions and no randomised controlled trials comparing proton with photon radiotherapy were identified in the included studies.1 point
  • Proton beam therapy is reported to have the potential to reduce late adverse events by reducing irradiation of non-target normal tissue compared with photon radiotherapy, but the evidence base consists largely of non-randomised studies and modelling assumptions; no randomised controlled trials comparing proton with photon radiotherapy were identified in the included studies. [4]
What we don't know yetImportant evidence gaps remain: adult pineoblastoma care is usually extrapolated from pediatric data because adult-specific studies are limited; prospective multicentric research is needed to define surgical strategies for pediatric pineal region tumours; and further studies are required to validate pooled Gamma Knife radiosurgery findings and to guide selection based on presumptive diagnosis.3 points
  • Multicentric prospective studies are needed to establish evidence-based surgical strategies for pediatric pineal region tumours. [3]
  • Further studies are needed to validate apparent efficacy and safety findings from pooled Gamma Knife radiosurgery reviews and to guide selection based on presumptive diagnosis. [5]
  • Sources describe limited adult-specific evidence—mainly single-institution retrospective analyses and a few case reports—insufficient to clarify treatment options. [2]

Common questions

What is Pineoblastoma?

Pineal region tumours are rare, mainly arise at a younger age, and include pineoblastoma among other histologies. Pineoblastoma is classified as a WHO grade IV tumour with a high rate of recurrence and propensity for spread via the cerebrospinal fluid (CSF).

How common is Pineoblastoma?

Pineal region tumours are rare. Primary pineal tumours make up a small fraction of intracranial malignancies, pineal tumours are a heterogeneous group in children, and pineoblastoma is a common pineal parenchymal subtype.

Which biomarkers are important in Pineoblastoma?

Germ cell tumours in the pineal region — but not pineoblastoma — can sometimes be identified by elevated tumour markers in CSF and serum such as alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG). Recent molecular characterisation has segregated pineoblastoma into five molecular subgroups (PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC) with distinct clinico-pathologic and survival features.

How is Pineoblastoma treated?

Pineal region tumors are typically evaluated with imaging and require histologic diagnosis by biopsy except when specific germ cell tumor markers identify the lesion; they commonly produce obstructive hydrocephalus and mass-effect symptoms such as headache, nausea, vomiting, and impaired gait stability. Management centers on surgical resection — benign pineal region tumors may be managed with radical resection alone, while malignant tumors commonly require additional chemotherapy and radiotherapy after surgical removal.

What treatments are studied for Pineoblastoma?

Eight entries covering procedure_device, radiotherapy, and chemotherapy approaches to pineoblastoma are reported.

What is the prognosis for Pineoblastoma?

In a pooled series of 108 adult pineoblastoma cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. In multivariate analysis, receipt of radiotherapy was associated with a substantially lower hazard of death (HR 0.16; p < 0.001), and patients who underwent surgery (GTR or STR) had superior overall survival at 5 and 10 years.

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 19, 2026.

  1. GuidelineConsensus guidelines for the management of pineal region tumours for low- and middle-income countries · 2024
  2. Systematic reviewA systematic review of adult pineoblastoma · 2024
  3. Systematic reviewSurgical management of pediatric pineal region tumors: an overview of current strategies · 2026
  4. Systematic reviewThe effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review · 2024
  5. Systematic reviewPrimary Gamma Knife Radiosurgery for pineal region tumors: A systematic review and pooled analysis of available literature with histological stratification · 2023

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
2
Meta-analysis
2
Systematic review
5
Randomized trial
2
Clinical trial
15
Observational
2
Case report
66
Review
224
Preclinical
0
Other
7

Living document — last change June 19, 2026: Cancer page updated. 2 recent updates logged.

Pooled evidence across studies

PubMed

Numbers pooled deterministically across 30 published studies that passed our figure-accuracy checks — a quick synthesis, not a formal meta-analysis. Updated 7/20/2026.

Medicines & supplements studied for Pineoblastoma

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Pineoblastoma, ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 1

MethotrexateHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies

Most authoritative study: Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group

Based on a single study.
OtherFDA off-labelPhase 31 studyFull profile →

What recent studies report in Pineoblastoma

These are reviewed studies whose abstracts concern Pineoblastoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Pineoblastoma. Most are early lab, animal, or small human studies, and findings often conflict.

32 studies8 human2 animal⚠ Conflicting evidenceMechanism (18)Trial (1)

Tracking 32 published studies of Pineoblastoma: 8 in humans, 2 in animals, 22 reviews/other.

Reported direction across studies: 12 positive, 5 mixed, 1 negative, 14 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Pineoblastoma.

Compounds with studies mentioning Pineoblastoma

Methotrexate (1)
ReviewMechanismInconclusiveModerate evidenceTier 4 · clinical

Histopathology and Molecular Pathology of Pineal Region Tumors

Advances and technical standards in neurosurgery · Jan 2026

pineal region tumorsgerm cell tumorspineal parenchymal tumorspineocytomapineal parenchymal tumor of intermediate differentiation (PPTID)pineoblastomagerminomapapillary tumor of the pineal region

This review chapter summarizes the histopathological features and molecular alterations of pineal-region tumors. It describes the main tumor groups (germ cell tumors and pineal parenchymal tumors), lists PPT subtypes (pineocytoma, PPTID, pineoblastoma), and highlights molecular findings such as microRNA biogenesis and RB pathway alterations in pineoblastoma, KBTBD4 insertions in PPTIDs, MAPK pathway mutations in germinomas, and chromosome 10 loss in papillary tumor of the pineal region.

Key findings
  • Pineal region tumors are rare, accounting for about 1% of central nervous system tumors.
  • The two most common pineal-region tumor types are germ cell tumors (GCTs) and pineal parenchymal tumors (PPTs).
  • PPTs include pineocytomas (well-differentiated), PPTIDs (intermediate differentiation), and pineoblastomas (poorly differentiated/high-grade).
  • Pineoblastoma molecular pathogenesis involves alterations in microRNA biogenesis and the retinoblastoma (RB) pathway.
  • PPTIDs are characterized by small in-frame insertions in KBTBD4.
  • Pineal germ cell tumors likely originate from overmigrated primordial germ cells and show the same histopathological spectrum as gonadal counterparts; germinomas frequently present mutations in the MAPK pathway.
  • Papillary tumor of the pineal region is a distinct ependymal-type tumor that shows loss of chromosome 10 in most cases.
Limitations: This is a narrative review/chapter and does not present original experimental or patient-level data.; Pineal-region tumors are rare (≈1%), so underlying studies and evidence are limited by tumor rarity.; The abstract provides no methodological details, sample sizes, or systematic review methods.; The abstract summarizes molecular associations but does not provide prognostic or therapeutic outcome data..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewReported positiveLimited evidenceTier 4 · clinical

Pineal Tumors and Pineal Region Tumors

Advances and technical standards in neurosurgery · Jan 2026 · narrative review

pineal region tumorspineal parenchymal tumors (PPTs)pineocytomapineal parenchymal tumor of intermediate differentiation (PPTID)pineoblastoma (PB)papillary tumor of the pineal region (PTPR)desmoplastic myxoid tumor, SMARCB1-mutantgerminomanon-germinomatous germ cell tumor (NGGCT)

This narrative review summarizes current radiotherapy principles for pineal region tumors (various pineal parenchymal tumors and germ cell tumors). It reports recommended radiation approaches and doses by subtype (e.g., adjuvant RT 50-54 Gy for some PPTs, CSI with boost for pineoblastoma, WVI 24 Gy + boost for germinomas) and notes survival outcomes reported in the literature (e.g., >90% 5-year OS for germinoma; >70% 5-year OS for older children with pineoblastoma). The authors highlight use of conformal and particle techniques and call for further dose-volume and biomarker-driven refinement.

Reported effects: adjuvant RT dose (pineocytoma) · adjuvant RT dose (PPTID) · +8 more

Studied with: surgery, chemotherapy.

Key findings
  • For pineocytoma (WHO grade I), gross total resection (GTR) provides excellent outcomes; adjuvant radiotherapy (50-54 Gy) or stereotactic radiosurgery (SRS) is reserved for subtotally resected cases.
  • PPTIDs (grades II-III): GTR is the main prognostic factor; adjuvant RT (50-54 Gy) improves overall survival; CSI (23-36 Gy + boost) is indicated for disseminated disease.
  • Pineoblastoma requires multimodal therapy: CSI (36 Gy + boost to 54-55.8 Gy) combined with chemotherapy yields 5-year OS rates >70% in children ≥3 years, but outcomes are poorer in younger or metastatic patients.
  • Papillary tumor of the pineal region (PTPR) often recurs locally; adjuvant focal RT (~50 Gy) is recommended.
  • Desmoplastic myxoid tumor, SMARCB1-mutant: limited data, but focal RT ≥54 Gy has been used.
  • Pure germinomas are highly radiosensitive and achieve >90% 5-year OS; reduced-volume RT (whole-ventricular irradiation, WVI, 24 Gy + boost) has replaced historical CSI for many cases.
  • Non-germinomatous germ cell tumors (NGGCTs) require combined chemotherapy and RT; CSI + boost achieves 70-90% 5-year OS.
  • Proton therapy and other particle techniques are increasingly used to reduce long-term neurocognitive and secondary malignancy risks.
  • Overall management relies on an integrated approach combining surgery, radiotherapy, and chemotherapy, with growing use of molecular classification to guide risk-adapted treatment.
Limitations: This is a narrative review (no original patient-level data or meta-analytic synthesis reported in the abstract).; Pineal region tumors are rare and heterogeneous, limiting the quality and quantity of evidence for some subtypes.; For some entities (e.g., desmoplastic myxoid tumor, SMARCB1-mutant) the abstract notes limited data supporting management recommendations.; Recommendations appear to be based on aggregated/prior literature rather than prospective randomized data (noted indirectly by review format)..

This review summarizes radiotherapy approaches and reported outcomes for pineal region tumors and is directly relevant to clinical radiotherapy planning for these neoplasms.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human trialTrialMixed resultsModerate evidenceTier 4 · clinicaln = 77

Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group

Neuro-oncology · Oct 2025 · phase 3 randomized controlled trial

Methotrexateembryonal brain tumorsmedulloblastomaGroup 3 medulloblastomaSHH medulloblastomaembryonal tumor with multilayered rosettespineoblastoma

This phase 3 randomized trial tested adding high-dose methotrexate to induction chemotherapy in children ≤36 months with high-risk embryonal brain tumors. Overall complete response rates were similar between arms, but in medulloblastoma patients methotrexate was associated with higher CR (63% vs 30%) and improved 5-year event-free survival in Group 3 medulloblastoma (70% vs 33.3%). No benefit was seen for embryonal tumor with multilayered rosettes or pineoblastoma.

Reported effects: eligible patients 77, n=77 · patients evaluated for response 59, n=59 · +8 more

Studied with: induction chemotherapy, high-dose consolidation chemotherapy with hematopoietic stem-cell infusion.

Key findings
  • Of 77 eligible patients, 59 with detectable disease were evaluated for response and 28 (47.5%) achieved CR; 15/30 (50%) treated with methotrexate compared to 13/29 (45%) without methotrexate (P&#x2005;=&#x2005;0.35).
  • For medulloblastoma (MB), CR was 12/19 (63%) with methotrexate compared to 6/20 (30%) without methotrexate (P&#x2005;=&#x2005;0.039).
  • All SHH subtype MB (n&#x2005;=&#x2005;11) were survivors (molecular characterization retrospective).
  • Five-year event-free survival (EFS) for Group 3 MB was 70% (90% CI: 39.6-87.2) with methotrexate versus 33.3% (90% CI: 15.0-52.9) without (P&#x2005;=&#x2005;0.037).
  • In other embryonal tumors, CR was 3/11 (27%) with methotrexate compared to 7/9 (78%) without (P&#x2005;=&#x2005;0.99).
  • No benefit observed for Embryonal Tumor with Multilayered Rosettes (n&#x2005;=&#x2005;14; EFS 20.0% [90% CI: 1.8-52.5] with methotrexate versus 33.3% [90% CI: 10.8-58.1] without, P&#x2005;=&#x2005;0.58) or pineoblastoma (n&#x2005;=&#x2005;9; EFS 16.7% [90% CI: 1.6-46.1] with methotrexate versus 0% without, P&#x2005;=&#x2005;0.52).
Limitations: Relatively small overall sample size (77 eligible) with smaller numbers in histologic/molecular subgroups; Molecular characterization was conducted retrospectively; Some subgroup analyses involve very small n (e.g., Group 3 MB: 10 vs 15; SHH MB n=11); Tests of significance were one-sided (as stated); Confidence intervals reported are 90% rather than the more conventional 95%.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Animal studyMechanismReported positivePreclinical onlyTier 2 · animal

Drosha: a new tumor suppressor in pineoblastoma

Genes & development · Jun 2025 · genetically engineered mouse models

pineoblastoma

Researchers used genetically engineered mouse models that represent different molecular subtypes of pineoblastoma to examine the roles of miRNA-processing enzymes Drosha and Dicer1. They found that loss of either Drosha or Dicer1 partially mimicked the tumorigenic effects of Rb1 deletion by promoting cell cycle progression via derepression of Plagl2 and cyclin D2. The study reports a novel mechanism in which disrupted miRNA processing can drive pineoblastoma development and notes that targeting downstream proliferative drivers could be a potential therapeutic strategy.

Key findings
  • Multiple genetically engineered mouse models representing distinct molecular subtypes of pineoblastoma were developed.
  • Loss of either Drosha or Dicer1 partially mimicked the tumorigenic effects of Rb1 deletion.
  • Loss of Drosha or Dicer1 promoted cell cycle progression through derepression of Plagl2 and cyclin D2.
  • Disrupted miRNA processing is reported as a novel mechanism driving pineoblastoma development.
  • Authors highlight a potential therapeutic strategy of targeting downstream proliferative drivers.
Limitations: Study was performed in mouse models only (no human interventional data reported).; Abstract provides no sample size, statistical details, or quantitative results.; Therapeutic strategy is suggested but not tested in this report..

Direct investigation of molecular drivers of pineoblastoma using mouse models; mechanistic relevance to tumorigenesis.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Animal studyMechanismReported positivePreclinical onlyTier 2 · animal

An imbalance between proliferation and differentiation underlies the development of microRNA-defective pineoblastoma

Genes & development · Jun 2025

pineoblastomapineal tumor

The authors deleted Drosha or Dicer1 in the developing mouse pineal gland to model microRNA-defective pineoblastoma. These mice developed pineal tumors with loss of microRNAs (notably let-7/miR-98-5p), derepression of microRNA target genes, and upregulation of S-phase genes and developmental homeobox transcription factors. Blocking tumor proliferation promoted expression of pinealocyte maturation markers and reduced some embryonic markers, and inhibiting signaling downstream of the oncofetal transcription factor Plagl2 impaired tumor growth. The study suggests that targeting downstream proliferation drivers may limit growth of tumors caused by loss of microRNA processing.

Key findings
  • Ablation of Drosha or Dicer1 in the developing pineal gland of mice produces pineal tumors characterized by loss of microRNAs, particularly the let-7/miR-98-5p family, and derepression of microRNA target genes.
  • Pineal tumors driven by Drosha or Dicer1 loss show upregulation of S-phase genes and homeobox transcription factors and phenocopy tumors driven by Rb1 loss.
  • Blocking proliferation in these tumors facilitates expression of pinealocyte maturation markers and reduces some embryonic markers, although select embryonic markers remain elevated due to continued absence of the repressing microRNAs.
  • Plagl2 is identified as a microRNA target and an oncofetal transcription factor that regulates progrowth genes; inhibiting Plagl2-related signaling impairs tumor growth.
Limitations: Animal (mouse) genetic-ablation model only — findings not demonstrated in human patients.; Study models genetic loss of microRNA processing (Drosha/Dicer1 ablation), which may not fully recapitulate the diversity of human tumor genetics.; No clinical or human data reported to support translational efficacy or safety of targeting the identified pathways..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismReported positiveLimited evidenceTier 4 · clinical

Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities

Cancers · Feb 2025

pineoblastoma

This review summarizes recent advances in pineoblastoma research, describing major molecular subtypes driven by DICER/DROSHA loss, RB1 loss, or cMYC activation and noting differing prognoses between them. It reports that mouse models have been developed for RB1-, DICER1- and DROSHA-driven subtypes (a MYC-driven model is not yet established) and discusses tumor cell of origin, progression, autophagy, and potential targetable vulnerabilities while highlighting that metastatic disease is incurable and standard treatments can impair neurocognitive function.

Key findings
  • Pineoblastoma comprises several major molecular subtypes: (i) loss of microRNA processing factors DICER and DROSHA, (ii) loss of RB1, and (iii) amplification/induction of cMYC.
  • The DICER/DROSHA subtype is characterized by a relatively good prognosis whereas RB1- and MYC-driven subtypes exhibit exceedingly poor prognosis.
  • Mouse models have recently been established for RB1-, DICER1- and DROSHA-driven pineoblastoma subtypes; a MYC-driven mouse model has not yet been established.
  • The review discusses disease biology including cell of origin, tumor progression, the role of autophagy, and describes targetable vulnerabilities that could inform future precision therapies.
  • Standard treatment (surgery, radiation, systemic chemotherapy) improves survival but compromises neurocognitive function; metastatic pineoblastoma is described as incurable.
Limitations: This article is a review and does not present new primary experimental or clinical data.; Many conclusions discussed are based on recent preclinical models and not yet validated in humans.; A MYC-driven pineoblastoma mouse model has not been established, limiting preclinical study of that high-risk subtype.; Pineoblastoma is a rare disease, which limits available clinical data and may hinder generalizability of findings..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalReported positiveLimited evidenceTier 3 · early humann = 108

A systematic review of adult pineoblastoma

Frontiers in oncology · Dec 2024 · systematic review

pineoblastoma

This systematic review pooled 108 adult pineoblastoma cases from 32 articles and analyzed survival outcomes. The reported 5-year survival rate was 49.5% and the 10-year survival rate was 33.9%. Gross total resection was associated with better survival than subtotal resection or no surgery (P=0.018), and radiotherapy and chemotherapy were associated with improved survival (P&lt;0.001; P=0.020); radiotherapy was an independent favorable factor in multivariate analysis (P&lt;0.001).

Reported effects: total cases included 108, n=108 · median age at diagnosis 30, n=108 · +7 more

Key findings
  • Total of 108 adult cases from 32 articles; median age at diagnosis was 30 years.
  • 5-year survival rate was 49.5% (95% confidence interval: 0.378-0.602).
  • 10-year survival rate was 33.9% (95% confidence interval: 0.207-0.476).
  • During 10-year follow-up, gross total resection was more beneficial than subtotal resection and no surgery (P=0.018).
  • Radiotherapy and chemotherapy were associated with improved survival (P&lt;0.001; P=0.020).
  • Multivariate COX analysis identified radiotherapy as an independent factor for beneficial prognosis (P&lt;0.001); gross total resection tended to improve 5-year survival (P=0.079).
Limitations: Small total case number (n=108) compiled from heterogeneous sources (case reports, single-institution series).; Retrospective and observational data; no randomized controlled trials included.; Potential selection and reporting bias across included studies.; Heterogeneity of treatments and follow-up across studies limits causal inference..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMixed resultsLimited evidenceTier 4 · clinical

SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors

Neuro-oncology · Dec 2024 · consensus review

pineal parenchymal tumorspineocytomapineal parenchymal tumor of intermediate differentiationpineoblastomapapillary tumor of the pineal region

This international consensus review summarizes diagnostic and treatment approaches for rare pineal parenchymal tumors and related intrinsic pineal masses. It highlights recent genomic findings that informed refinements in the WHO 5th edition molecular classification and offers pragmatic clinical management recommendations ranging from surgery alone to intensive multimodal antineoplastic therapy.

Key findings
  • Pineal parenchymal tumors are rare and lack robust evidence-based treatment recommendations.
  • These tumors vary in biology, clinical characteristics, and prognosis, necessitating a range of treatments from surgical resection alone to intensive multimodal antineoplastic therapy.
  • Recent international genomic studies have refined the molecular-based disease classification, incorporated in the WHO 5th edition.
  • The review summarizes literature on diagnostic and therapeutic approaches and suggests pragmatic recommendations for clinical management of intrinsic pineal region masses (pineocytoma, PPTID, pineoblastoma), pineal cyst, and papillary tumors of the pineal region.
Limitations: Tumors are rare and high-quality evidence is sparse, limiting strength of recommendations.; Recommendations are based on literature review and consensus rather than randomized controlled trials.; Heterogeneity of tumor biology and prognosis may limit generalizability of suggested management approaches.; No new primary quantitative data are reported in this review..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewReported positiveLimited evidenceTier 4 · clinical

Pineal/germ cell tumors and pineal parenchymal tumors

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · Oct 2023 · Review

pineal region tumorspineal parenchymal tumorsgerm cell tumorspineoblastomaneuroepithelial tumors

This review summarizes the types, diagnosis, and management of pineal region tumors across age groups, with emphasis on germ cell tumors and pineal parenchymal tumors. It reports that germ cell tumors predominate in children and young adults while pineal parenchymal tumors and neuroepithelial tumors are common in all ages, and that MRI plus serum/CSF AFP and β-HCG aid diagnosis. The authors state that advances in endoscopic and microsurgical approaches since the 1970s have reduced mortality and morbidity, and that molecular profiling has identified four molecular groups of pineoblastoma enabling molecularly stratified therapy. Future directions discussed include molecular analysis of CSF/blood and AI radiomics to support personalized, risk-stratified management.

Key findings
  • Pineal region tumors are rare and heterogeneous; they account for 2.8-10.1% of tumors in children and 0.6-3.2% in all ages.
  • In all ages in western countries the leading three types of PRTs were pineal parenchymal tumors (22.7-34.8%), germ cell tumors (27.3-34.4%), and neuroepithelial tumors (17.2-28%).
  • In children and young adults the leading PRTs were in the order of germ cell tumors (40-80.5%), pineal parenchymal tumors (7.6-21.6%), and neuroepithelial tumors (2.4-37.5%).
  • MRI of the brain (with and without gadolinium) with sagittal spine imaging, and serum and/or CSF AFP/β-HCG, are important for diagnosis and identification of germ cell tumors.
  • Surgical biopsy/resection is important for precise diagnosis and therapy, and safe resection with acceptable low mortality and morbidity has been achieved after the 1970s due to advances in surgical approaches, CSF shunting, and endoscopic/microscopic techniques.
  • Molecular profiling has identified four molecular groups of pineoblastoma and their oncogenic drivers, supporting potential molecular-stratified precision therapy.
  • The review highlights the roles of endoscopy, adjuvant chemotherapy and radiotherapy, and suggests future integration of molecular biospecimen analysis and AI radiomics.
Limitations: Narrative review article; no primary patient-level data or methods reported in the abstract.; Rarity and heterogeneity of pineal region tumors limit generalizability and high-quality evidence.; Abstract provides summary-level statements without details on study selection, sample sizes, or levels of evidence for recommendations..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismInconclusiveModerate evidenceTier 4 · clinical

Histopathology and molecular pathology of pediatric pineal parenchymal tumors

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · Sep 2023 · narrative review

pineoblastomapineal parenchymal tumor of intermediate differentiation (PPTID)retinoblastoma

This review summarizes the histopathology and molecular classification of pediatric pineal parenchymal tumors. It states that pineoblastoma (WHO grade 4) and PPTID (WHO grade 2-3) are the two main types, that pineoblastoma splits into four molecular groups with differing age distributions and prognoses, and that PPTIDs commonly harbor small in-frame KBTBD4 insertions.

Key findings
  • Pineal parenchymal tumors in children are rare and comprise two main types: pineoblastoma (PB, WHO grade 4) and PPTID (WHO grade 2-3).
  • Pineoblastomas are divided into four molecular groups: PB-miRNA1, PB-miRNA2, PB-RB1, and PB-MYC/FOXR2.
  • PB-RB1 and PB-MYC/FOXR2 affect young children and are associated with a dismal prognosis; PB-miRNA1 and PB-miRNA2 affect older children and have a more favorable course.
  • PB-miRNA groups are characterized by mutually exclusive alterations in miRNA biogenesis genes (DICER1, DROSHA, DGCR8) and may be sporadic or part of DICER1 syndrome.
  • PB-RB1 tumors show RB1 alterations and can occur in the setting of congenital retinoblastoma (trilateral retinoblastoma).
  • In pediatric patients, PPTIDs typically affect adolescents and are characterized by small in-frame insertions in KBTBD4, a gene involved in ubiquitination.
Limitations: This is a review article and does not present new primary patient-level data.; The subject tumors are rare, so underlying published data are likely limited in size.; Prognostic associations described are summary statements from the literature and may be based on small cohorts..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Meta-analysisMechanismMixed resultsLimited evidenceTier 4 · clinicaln = 118

A systematic review of the clinicopathological features and prognostic outcomes of DICER1-mutant malignant brain neoplasms

Journal of neurosurgery. Pediatrics · Jul 2022 · systematic review of individual patient data from case reports and small case series

embryonal tumor with multilayered rosettes (ETMR)pineoblastomaprimary intracranial sarcomapituitary blastoma

The authors performed a systematic review of studies reporting individual patients with primary malignant brain tumors carrying DICER1 mutations and pooled data from 118 cases across four tumor types. They report that pineoblastoma, ETMR, and pituitary blastoma more often had germline DICER1 mutations, nearly 80% of tumors with germline mutations also had an additional somatic DICER1 mutation, ETMR and intracranial sarcoma had higher relapse risk, and gross-total resection plus radiotherapy were associated with longer overall survival.

Reported effects: difference in germline DICER1 mutation prevalence across tumor types, p <0.001 · tumors with germline DICER1 mutation that also had another somatic DICER1 mutation 80% · +1 more

Key findings
  • Identified 16 studies comprising 9 ETMRs, 30 pineoblastomas, 52 primary intracranial sarcomas, and 27 pituitary blastomas (total n = 118).
  • Pineoblastoma, ETMR, and pituitary blastoma were more likely to carry DICER1 germline mutations, while only a small subset of primary intracranial sarcomas harbored these mutations (p < 0.001).
  • Nearly 80% of tumors with germline mutations also had another somatic mutation in DICER1.
  • ETMR and primary intracranial sarcoma were associated with an increased risk for tumor progression and relapse compared with pituitary blastoma and pineoblastoma (p = 0.0025).
  • Overall survival (OS) was not significantly different between the tumor types.
  • Gross-total resection (GTR) and radiotherapy administration were associated with prolonged OS.
  • Authors conclude these tumor types should be considered rare phenotypes of DICER1 syndrome and families should be counseled and screened for associated tumors.
Limitations: Review is based on published case reports and small case series, as stated by the authors.; Potential selection and publication bias inherent to retrospective case-report-based data.; Heterogeneity across included reports (tumor types, treatments, and reporting) likely limits comparability.; No randomized or prospective controlled data available in the included studies..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMixed resultsLimited evidenceTier 3 · early humann = 1133

Epidemiology of pineoblastoma in the United States, 2000-2017

Neuro-oncology practice · Jan 2022 · population-based registry analysis

pineoblastoma

This population-based registry study analyzed 1,133 US patients with pineoblastoma from 2000–2017 to describe incidence and survival. Incidence was highest in children ages 0–4 and was higher in Black versus White patients; survival was worse for males, very young children, elderly adults, and patients who did not undergo surgery. The study provides national epidemiologic estimates but is observational and cannot establish causation.

Reported effects: AAIR ages 0-4 per 100,000 0.049 [0.042–0.056], n=1133 · IRR Black vs White 1.71 [1.48–1.98], p P < .001, n=1133 · +2 more

Key findings
  • Incidence was highest in ages 0-4 years (AAIR: 0.049 per 100,000, 95% CI: 0.042-0.056).
  • Incidence was higher among patients who are Black compared to patients who are White (IRR: 1.71, 95% CI: 1.48-1.98, P < .001).
  • Black-to-White incidence was highest in children ages 5-9 years (IRR: 3.43, 95% CI: 2.36-4.94, P < .001).
  • Overall survival was lower for males (HR: 1.39, 95% CI: 1.07-1.79, P = .013).
  • All age groups except those over 40 had improved survival compared to ages 0-4 years.
  • Those who received surgical intervention had better survival compared to those who did not receive surgical treatment.
Limitations: Observational, registry-based design — cannot establish causation.; Registry data may lack detailed clinical, molecular, or treatment variables and may be subject to miscoding/missing data.; Survival analysis period (2001-2016) differs slightly from incidence period (2000-2017), which may affect comparability across analyses..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Pineoblastoma →

Study mix

32 published studies by what they were done in. Lab and animal findings often do not carry over to people.

8 Human2 Animal22 Review/other
Reported directionReported positive12Mixed results5Reported negative1Inconclusive14

Evidence at a glance: compounds studied in Pineoblastoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

MethotrexateHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies

Most authoritative study: Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group

Based on a single study.

What the research shows for Pineoblastoma

A plain-language summary of the reviewed studies OncoForge tracks for Pineoblastoma. It reports what those studies described, not a claim that any compound or therapy helps or harms Pineoblastoma. Most of this evidence is early, and findings often conflict.

  • Studies report that germline DICER1 pathogenic variants are associated with a spectrum of pediatric tumors and that several reviews and expert-consensus documents include pineoblastoma among the CNS manifestations linked to DICER1, based mainly on genetic and case-series evidence.
  • A small retrospective imaging series of children with germline DICER1 variants reported a range of DICER1‑associated malignant and benign lesions and included pineoblastoma among the observed tumors, but the sample size was limited.
  • An international consensus review summarizes diagnostic and treatment approaches for pineal parenchymal tumors and notes recent genomic findings that informed molecular classification refinements; evidence remains limited by the rarity of these tumors.
  • A phase 3 randomized trial studied adding high‑dose methotrexate to induction chemotherapy in children ≤36 months with high‑risk embryonal brain tumors and reported mixed outcomes (with subgroup differences in medulloblastoma), but it did not provide pineoblastoma‑specific data, so applicability is uncertain.

Compounds studied in Pineoblastoma

Methotrexate1 study
In these studies, high‑dose methotrexate was evaluated in a phase 3 randomized trial of young children with high‑risk embryonal brain tumors where results were mixed overall and showed subgroup differences in medulloblastoma, but the trial did not report pineoblastoma‑specific outcomes, limiting applicability to pineoblastoma.

Supportive & alternative options discussed

  • Hyperthermia (heat): Also discussed as a supportive or adjunctive option in brain tumor care, but the studies summarized here did not evaluate hyperthermia for pineoblastoma.
  • Acupuncture: Also discussed as a supportive option for symptom management in people with brain tumors; these studies did not assess acupuncture in pineoblastoma patients.
  • Exercise / prehabilitation: Also discussed as a supportive approach to preserve function and quality of life in brain tumor survivors; the cited studies did not investigate exercise in pineoblastoma specifically.
  • Mind–body (MBSR / CBT): Also discussed as a supportive option for psychological symptom management in brain tumor care; the provided studies did not address mind–body interventions for pineoblastoma.
  • Ketogenic / metabolic therapy: Also discussed by some as a complementary dietary approach for brain tumors, but the studies in this collection did not evaluate the ketogenic diet in pineoblastoma.

What we don’t know yet

  • Do high‑dose methotrexate or other specific chemotherapy regimens provide benefit (or harm) for patients with pineoblastoma specifically?
  • How do molecular subgroups of pineoblastoma (including DICER1‑associated cases) affect optimal therapy and prognosis?
  • What are the long‑term outcomes, late effects, and quality‑of‑life impacts after current multimodality treatments for pineoblastoma in children?
  • What are appropriate surveillance and management strategies for individuals with germline DICER1 variants regarding pineal tumors, based on prospective data?
  • Are there adequately powered, prospective clinical trials focused on pineoblastoma to guide treatment decisions?
Overall, the evidence relevant to pineoblastoma in these studies is limited and mainly consists of genetic/observational reports, expert consensus, and indirect clinical trial data from other embryonal brain tumors, so firm conclusions about specific treatments for pineoblastoma cannot be drawn from this set of studies.

Clinical trials in Pineoblastoma

11 ongoing · 44 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
15 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Pineoblastoma — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN Foundation ↗ — Copay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell Foundation ↗ — Copay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistance ↗ — Limited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family Reach ↗ — Help with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMeds ↗ — Searchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →